RxDoctor Payments Data

Boutros Karam, MD

Cardiovascular Disease · Brooklyn, NYNPI 1982010294

Payments from drug & device makers

$4,399in general payments, 2019–2025

Across 47 payments — averaging $93.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Shockwave Medical, Inc$615
  • Janssen Scientific Affairs, LLC$322
  • Philips North America LLC$267
  • Medtronic$164
  • Chiesi USA, Inc.$132
  • plus $337 from 9 others

What the payments were for

  • Grants$1,10525%
  • Food & beverage$3,29475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,399 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$175,634
Medicare patients
587
Services billed
1,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$48,984
EntrestoSacubitril/Valsartan29$23,878
JardianceEmpagliflozin26$18,883
Repatha SyringeEvolocumab12$6,300
Metoprolol Succinate182$2,676
Ranolazine ErRanolazine37$2,266
Rosuvastatin Calcium110$1,989
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,903
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$1,605
Atorvastatin Calcium115$962
Losartan Potassium78$794
Ezetimibe48$671
ClopidogrelClopidogrel Bisulfate85$629
Isosorbide Mononitrate ErIsosorbide Mononitrate65$627
Amlodipine Besylate85$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$48,98460 claims
NovartisEntresto$15$23,87829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →